SOD2 and thanatophoric dysplasia: In conclusion, our study demonstrated that 12 weeks of EGb761 treatment improved TD symptoms and enhanced low MnSOD activity, especially in TD patients with the Ala allele of the MnSOD Ala-9Val polymorphism.